Using bladder & ovarian cancer cells, they demonstrated that neratinib resistant cells showed enrichment of cell cycle promoting E2F targets, along with nuclear factor kappa B (NF-KB), epithelial-to-mesenchymal transition, KRAS, TORC1, inflammation, and immunological signatures. The gene discussed is CRTC1; the disease is ovarian carcinoma.